呼吸器疾患検査市場：検査タイプ、成分、年齢層、技術、検査目的、疾患タイプ、エンドユーザー別-2025-2030年世界予測

呼吸器疾患検査市場は、2024年に64億9,000万米ドルと評価され、2025年には68億6,000万米ドル、CAGR 5.95%で成長し、2030年には91億8,000万米ドルに達すると予測されています。

イントロダクション

呼吸器疾患検査市場は、ヘルスケアにおいて最もダイナミックで急速に発展している分野の一つとして浮上しています。科学的イノベーションとタイムリーな診断の必要性が融合する環境において、この市場は先進的な検査方法の重要性を実証しています。最近の動向は、精度の向上、所要時間の短縮、コスト効率の必要性を強調しており、これらが診断アプローチの絶え間ない進化を後押ししています。こうした開発の結節点には、画期的な診断手法、進化する規制の枠組み、患者の意識の高まりがあり、これらすべてが業界を精密医療の新時代へと押し上げています。

テクノロジーと従来の診断手法との融合は、患者管理とヘルスケア提供の強化に道を開いた。診断検査機関、病院、研究機関が多面的な検査プロトコルの利点を認識するにつれ、業界は技術革新と業務効率の合流から利益を得ています。このような環境は、イノベーターとエンドユーザーとの戦略的パートナーシップを促進し、新たなヘルスケア動向に継続的に適応する強固な市場を生み出しています。その結果、利害関係者は現在、転帰を改善するだけでなく、より質の高いケアのために臨床経路を合理化する先進的な呼吸器疾患検査ソリューションに投資することが不可欠な立場にあることに気づいています。

呼吸器疾患検査市場の変革

近年、呼吸器疾患検査の展望を再定義する変革的な変化が起きています。技術革新と規制の変革は、精密性と効率性への欲求に後押しされ、新たな診断方法が急速に受け入れられるエコシステムを育んできました。治療技術は従来の方法をはるかに超えて進化し、高度な画像診断システム、自動分析装置、最先端の分子プラットフォームへの道を開き、診断の信頼性を高めると同時に、治療までの時間を短縮しています。

規制機関は、早期承認の範囲を拡大しただけでなく、高水準の精度と信頼性を保証する厳しい基準を設定しています。こうした変化により、メーカー各社はコンプライアンスと革新性を両立させた製品の開発を優先せざるを得なくなっています。個別化医療への新たな注目は、患者固有の呼吸器疾患の理解を深めるのに役立つデジタルヘルスとデータ解析の開発によってさらに支えられています。臨床医がリアルタイムのデータとデジタル診断にますます依存するようになるにつれ、検査プロセス全体がより効率的で患者中心のものとなっています。遠隔地や在宅ケア環境におけるポイントオブケア検査の普及は、ヘルスケア提供のアクセシビリティと質の両方を高める分散型診断能力へのシフトをさらに明確に示しています。

主なセグメンテーションの洞察

市場セグメンテーションから得られた洞察は、呼吸器疾患に対応する様々な検査モダリティをより深く理解するための、微妙な状況を明らかにしています。検査タイプに基づく分類には、血液検査、画像検査、肺機能検査が含まれ、画像検査はさらに胸部X線検査とコンピュータ断層撮影に分けられ、放射線診断への詳細なアプローチが強調されています。検査タイプの分析に加え、コンポーネント別のセグメンテーションによると、市場は機器、試薬・キット、専用ソフトウェアといった異なる要素で構成されており、これらすべてが診断システム全体において極めて重要な役割を果たしています。

さらなるセグメンテーションでは、市場が成人、老年、小児にまたがって調査されている人口統計学的区分の重要性が強調されています。この区分により、検査プロトコルが年齢層間の生理学的差異にうまく適合することが保証されます。技術的進歩はマーケットプレースの差別化を促進し、技術に基づくセグメンテーションはイメージング技術、免疫測定法、微生物学、分子診断学の開発を特徴づける。市場評価では、診断、モニタリング、予後予測、スクリーニングを区別することで、検査の多様な目的も考慮しています。

疾患別の詳細なセグメンテーションでは、喘息、慢性閉塞性肺疾患（COPD）、感染性呼吸器疾患、肺がんのために開発された検査に光を当てています。COPDの中では、慢性気管支炎や肺気腫などの追加層が考慮されており、感染性呼吸器疾患はさらにインフルエンザ、肺炎、結核に分類され、包括的な疾患カバレッジを提供しています。最後に、診断ラボや在宅医療現場から病院、診療所、調査ラボまで、エンドユーザーに基づくセグメンテーションにより、診断プロセスにおけるすべての利害関係者の多様なニーズに徹底的に対応することができます。この多角的なセグメンテーションアプローチは、呼吸器疾患検査市場における戦略的意思決定と将来のイノベーションのためのバックボーンとして機能します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 呼吸器疾患に対する意識の高まりと罹患率の増加により、高度な検査が必要となっています。
    • 政府の取り組みと資金提供により、呼吸器診断の研究開発が促進されています。
    • 世界の大気汚染レベルの上昇が呼吸器疾患の増加と検査需要の増加につながっている
  • 抑制要因
    • 新しい診断技術の開発と導入に伴う高コスト
  • 機会
    • 診断テストの精度と速度を向上させる人工知能とデータ分析の統合
    • パーソナライズされたヘルスケアソリューションの需要の急増が呼吸器検査の進歩を促進
  • 課題
    • 呼吸器疾患検査ソリューションに関連する規制およびコンプライアンスの課題
• 市場セグメンテーション分析
  • 構成要素：呼吸器疾患の罹患率の上昇により、試薬とキットの必要性が高まっている
  • エンドユーザー：診断ラボは、ハイスループットで詳細な分析を可能にするため、重要性が高まっています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 呼吸器疾患検査市場テストの種類別

• 血液検査
• 画像検査
  • 胸部X線検査
  • コンピュータ断層撮影
• 肺機能検査

第7章 呼吸器疾患検査市場：コンポーネント別

• 機器
• 試薬とキット
• ソフトウェア

第8章 呼吸器疾患検査市場：年齢層別

• 大人
• 老年医学
• 小児科

第9章 呼吸器疾患検査市場：技術別

• イメージングテクノロジー
• 免疫測定
• 微生物学
• 分子診断

第10章 呼吸器疾患検査市場テスト目的別

• 診断
• 監視
• 予後
• スクリーニング

第11章 呼吸器疾患検査市場病気の種類別

• 喘息
• 慢性閉塞性肺疾患（COPD）
  • 慢性気管支炎
  • 肺気腫
• 感染性呼吸器疾患
  • インフルエンザ
  • 肺炎
  • 結核
• 肺がん

第12章 呼吸器疾患検査市場：エンドユーザー別

• 診断検査室
• 在宅ケア設定
• 病院と診療所
• 調査室

第13章 南北アメリカの呼吸器疾患検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第14章 アジア太平洋地域の呼吸器疾患検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第15章 欧州・中東・アフリカの呼吸器疾患検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第16章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• AstraZeneca PLC
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Biomerieux PLC
• Charles River Laboratories
• COSMED srl
• Eurofins Viracor, LLC
• F. Hoffmann-La Roche Ltd.
• Fujifilm Holdings
• GE Healthcare
• Koninklijke Philips N.V
• Medtronic PLC
• MGC Diagnostics Corporation by Caire Inc.
• QIAGEN Group
• ResMed
• SDI Diagnostics, Inc.
• Seegene Inc.
• Seimens Healthineers AG
• Thermo Fisher Scientific

LIST OF FIGURES

• FIGURE 1. RESPIRATORY DISEASE TESTING MARKET MULTI-CURRENCY
• FIGURE 2. RESPIRATORY DISEASE TESTING MARKET MULTI-LANGUAGE
• FIGURE 3. RESPIRATORY DISEASE TESTING MARKET RESEARCH PROCESS
• FIGURE 4. RESPIRATORY DISEASE TESTING MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
• FIGURE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 25. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 29. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 30. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 31. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. RESPIRATORY DISEASE TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RESPIRATORY DISEASE TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 59. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 80. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 81. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 82. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 83. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 84. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 86. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 87. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 88. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 89. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 97. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 98. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 99. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 108. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 109. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 110. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 120. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 129. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 130. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 131. AUSTRALIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 132. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 133. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 134. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 135. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 136. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 138. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 139. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 140. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 141. CHINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 142. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 143. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 144. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 145. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 146. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 147. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 148. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 149. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 150. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 151. INDIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 157. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 159. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 160. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 161. INDONESIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 167. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 169. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 170. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 171. JAPAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 177. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 179. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 180. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 181. MALAYSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 187. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 189. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 190. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 191. PHILIPPINES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 197. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 199. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 200. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 201. SINGAPORE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 210. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH KOREA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 217. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 219. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 220. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 221. TAIWAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 227. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 229. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 230. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 231. THAILAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 237. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 239. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 240. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 241. VIETNAM RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 258. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 260. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 261. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 262. DENMARK RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 268. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 270. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 271. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 272. EGYPT RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 278. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 280. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 281. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 282. FINLAND RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 288. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 290. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 291. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 292. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 295. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 296. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 298. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 299. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 300. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
• TABLE 301. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2030 (USD MILLION)
• TABLE 302. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 308. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
• TABLE 309. ISRAEL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2030 (USD MILLION)
• TABLE 310. ISRAEL RESPIRATORY D

The Respiratory Disease Testing Market was valued at USD 6.49 billion in 2024 and is projected to grow to USD 6.86 billion in 2025, with a CAGR of 5.95%, reaching USD 9.18 billion by 2030.

Introduction

The respiratory disease testing market has emerged as one of the most dynamic and rapidly evolving sectors in healthcare. In an environment where scientific innovations and the need for timely diagnosis are converging, this market has demonstrated the critical importance of advanced testing modalities. Recent trends have underscored the necessity for improved accuracy, faster turnaround times, and cost efficiency, which together drive the continuous evolution of diagnostic approaches. At the nexus of these developments lie groundbreaking diagnostic methodologies, evolving regulatory frameworks, and increasing patient awareness, all of which have propelled the industry into a new era of precision medicine.

The integration of technology with traditional diagnostic methods has paved the way for enhanced patient management and healthcare delivery. As diagnostic laboratories, hospitals, and research institutions recognize the advantages of multifaceted testing protocols, the industry benefits from a confluence of innovation and operational efficiency. This environment fosters strategic partnerships between innovators and end users, resulting in a robust market that continuously adapts to emerging healthcare trends. Consequently, stakeholders now find themselves in an imperative position to invest in advanced respiratory disease testing solutions that not only improve outcomes but also streamline clinical pathways for a better quality of care.

Transformative Shifts in the Landscape

Recent years have seen transformative shifts that are redefining the respiratory disease testing landscape. Technological innovations and regulatory transformations have fostered an ecosystem where new diagnostic modalities are gaining rapid acceptance, driven by a desire for precision and efficiency. Testing technologies have evolved far beyond conventional methods, making way for advanced imaging systems, automated analyzers, and state-of-the-art molecular platforms that increase the confidence in diagnosis while reducing the time to treatment.

Regulatory bodies have not only expanded the scope for accelerated approvals but have also set stringent standards that ensure high levels of accuracy and reliability. These changes have compelled manufacturers to prioritize the development of products that are both compliant and innovative. The emerging focus on personalized medicine is further supported by developments in digital health and data analytics, which help to better understand patient-specific respiratory conditions. As clinicians increasingly rely on real-time data and digital diagnostics, the entire testing process becomes more efficient and patient-centric. The propagation of point-of-care testing in remote settings and home care environments further underlines the shift toward decentralized diagnostic capabilities, which enhance both accessibility and quality of healthcare delivery.

Key Segmentation Insights

Insights drawn from market segmentation reveal a nuanced landscape that provides a deeper understanding of the various testing modalities catering to respiratory diseases. The categorization based on test type includes blood tests, imaging tests, and pulmonary function tests, where imaging tests are further dissected into chest X-ray and computed tomography, emphasizing the detailed approach to radiologic diagnostics. In addition to test type analysis, segmentation by component shows that the market comprises distinct elements such as instruments, reagents and kits, and specialized software, all of which play a pivotal role in the overall diagnostic system.

Further segmentation highlights the importance of demographic distinctions where the market is studied across adults, geriatrics, and the pediatric population; this categorization ensures that testing protocols are well-tailored to the physiological differences across age groups. Technological advancements help drive differentiation in the marketplace as segmentation based on technology characterizes the developments in imaging technologies, immunoassays, microbiology, and molecular diagnostics. The market evaluation also considers the varied purposes of tests by distinguishing diagnosis, monitoring, prognosis, and screening, each representing a different stage in the patient management continuum.

A detailed disease-specific segmentation sheds light on the tests developed for asthma, chronic obstructive pulmonary disease (COPD), infectious respiratory diseases, and lung cancer. Within COPD, additional layers such as chronic bronchitis and emphysema are taken into account, while infectious respiratory diseases further break down into influenza, pneumonia, and tuberculosis, offering comprehensive disease coverage. Lastly, segmentation based on end users-from diagnostic laboratories and home care settings to hospitals, clinics, and research laboratories-ensures that the diverse needs of all stakeholders in the diagnostic process are thoroughly met. This multidimensional segmentation approach serves as the backbone for strategic decision-making and future innovations within the respiratory disease testing market.

Based on Test Type, market is studied across Blood Tests, Imaging Tests, and Pulmonary Function Tests. The Imaging Tests is further studied across Chest X-Ray and Computed Tomography.

Based on Component, market is studied across Instruments, Reagents & Kits, and Software.

Based on Age Group, market is studied across Adults, Geriatrics, and Pediatrics.

Based on Technology, market is studied across Imaging Technologies, Immunoassays, Microbiology, and Molecular Diagnostics.

Based on Test Purpose, market is studied across Diagnosis, Monitoring, Prognosis, and Screening.

Based on Diseases Type, market is studied across Asthma, Chronic Obstructive Pulmonary Disease (COPD), Infectious Respiratory Diseases, and Lung Cancer. The Chronic Obstructive Pulmonary Disease (COPD) is further studied across Chronic Bronchitis and Emphysema. The Infectious Respiratory Diseases is further studied across Influenza, Pneumonia, and Tuberculosis.

Based on End Users, market is studied across Diagnostic Laboratories, Home Care Settings, Hospitals & Clinics, and Research Laboratories.

Key Regional Insights

Regional analysis has uncovered significant trends that vary across global markets, providing a comprehensive understanding of geographic trends and consumer behavior in the respiratory disease testing space. In the Americas, advancements in healthcare infrastructure and a well-established network of diagnostic centers contribute to a considerable market share. North America, in particular, is characterized by robust investments in cutting-edge technology and innovative testing protocols, driving the region toward high diagnostic accuracy and turnaround efficiency.

In the region comprising Europe, the Middle East, and Africa, the market is witnessing balanced growth driven by progressive healthcare reforms and a concerted focus on cancer and infectious disease prevention strategies. Evolving reimbursement policies and increasing governmental emphasis on early diagnosis further boost market growth here. On the other hand, the Asia-Pacific region has emerged as a vibrant market with rapid urbanization and significant improvements in healthcare delivery systems. A combination of rising disposable incomes and increased awareness of respiratory diseases has significantly expanded the patient pool for advanced diagnostic services in this region.

Collectively, these regional variations illustrate how socio-economic factors, infrastructure development, and governmental policies intertwine to shape the growth trajectories and operational dynamics of the respiratory disease testing market worldwide. The diverse regional insights aid industry players in tailoring their approaches to meet specific market demands and remain competitive on a global scale.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

An analysis of the leading companies in the respiratory disease testing market highlights a cohort of industry frontrunners who are driving innovation and market expansion. Several major players have established themselves as pioneers by investing in research and development, technology innovation, and strategic partnerships. Prominent names in the field-ranging from globally recognized conglomerates to specialized diagnostic firms-leverage their expertise to offer state-of-the-art testing solutions that meet rigorous international standards. For example, companies such as Abbott Laboratories, AstraZeneca PLC, and Becton, Dickinson and Company have long histories of reliability and advancement in the healthcare diagnostics space.

Other notable contributors like Bio-Rad Laboratories, Inc. and Biomerieux PLC are recognized for their commitment to enhancing diagnostic accuracy through innovative reagents and cutting-edge instrumentation. Prestigious organizations including Charles River Laboratories and COSMED srl complement these efforts by offering supportive expertise across various research and clinical settings. Additionally, firms such as Eurofins Viracor, LLC, F. Hoffmann-La Roche Ltd., and Fujifilm Holdings have made significant strides in integrating imaging technologies into their testing suites.

Leading healthcare technology providers like GE Healthcare and Koninklijke Philips N.V extend their reach across multiple facets of diagnostic imaging and software integration, ensuring that advanced diagnostic opportunities continue to proliferate. Further, Medtronic PLC and MGC Diagnostics Corporation by Caire Inc. break new ground in integrating diagnostics with patient care solutions, while QIAGEN Group, ResMed, SDI Diagnostics, Inc., Seegene Inc., Seimens Healthineers AG, and Thermo Fisher Scientific lend their technological prowess to refine and optimize testing workflows. The collective efforts of these companies have not only pushed the envelope of innovation but have also expanded market reach by ensuring comprehensive diagnostic service offerings that are agile in the face of evolving market demands.

The report delves into recent significant developments in the Respiratory Disease Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux PLC, Charles River Laboratories, COSMED srl, Eurofins Viracor, LLC, F. Hoffmann-La Roche Ltd., Fujifilm Holdings, GE Healthcare, Koninklijke Philips N.V, Medtronic PLC, MGC Diagnostics Corporation by Caire Inc., QIAGEN Group, ResMed, SDI Diagnostics, Inc., Seegene Inc., Seimens Healthineers AG, and Thermo Fisher Scientific. Actionable Recommendations for Industry Leaders

Industry players are advised to consider a multifaceted strategy to navigate the evolving respiratory disease testing market. A keen emphasis on research and development, combined with strategic investments in automation and digital analytics, can enhance diagnostic accuracy and operational efficiency. Leaders should focus on fostering strong alliances with technology developers to co-create innovative solutions that meet emerging clinical needs.

It is crucial to leverage the strengths derived from detailed segmentation studies to tailor product offerings that cater to specific sub-segments within the market. For instance, tailoring solutions for different age groups requires an in-depth understanding of physiological variations, while segment-specific technology investments-in imaging, immunoassays, and molecular diagnostics-promise to yield significant returns. Decision-makers should also adopt agile regulatory strategies that anticipate changes in global standards and swiftly align product innovation with compliance requirements.

Furthermore, expanding regional footprints in emerging markets-particularly in Asia-Pacific and regions with evolving healthcare infrastructures-can pave the way for enhanced market penetration. Comprehensive market intelligence, combined with timely strategic adjustments, will enable companies to stay ahead in this rapidly evolving space. Leaders are encouraged to invest in workforce training and the integration of advanced technologies to ensure that staff are adept at managing and interpreting sophisticated diagnostic data. Ultimately, a commitment to continuous innovation and a robust understanding of global market dynamics will provide the necessary competitive edge in a challenging marketplace.

Conclusion

In summary, the respiratory disease testing market is at a pivotal juncture, marked by technological advancements, evolving regulatory landscapes, and intricate segmentation dynamics. The convergence of technological innovation, demographic diversification, and regional variations is paving the way for a more precise and patient-centered diagnostic paradigm. As markets continue to transform, stakeholders must critically assess emerging trends and adapt strategies to harness the opportunities presented by innovative testing modalities.

This comprehensive overview underscores the significance of adopting a data-driven approach to understand market needs and regulatory pressures. The dynamic interplay between industry giants and emerging innovators further establishes a competitive environment where continuous innovation is not just an option, but a necessity. Enhanced diagnostic accuracy, coupled with streamlined operational processes, plays an integral role in the transition from traditional to cutting-edge respiratory disease testing methods. The future trajectory of this market will undoubtedly be shaped by sustained investments in technology, strategic partnerships, and a proactive approach to meet evolving clinical demands.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Expanding awareness and increasing prevalence of respiratory illnesses necessitate advanced testing
    • 5.1.1.2. Government initiatives and funding are bolstering research and development of respiratory diagnostics
    • 5.1.1.3. Rise in pollution levels worldwide contributing to increased respiratory ailments and testing demand
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with the development and implementation of new diagnostic technologies
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of artificial intelligence and data analytics in improving diagnostic test accuracy and speed
    • 5.1.3.2. Surge in demand for personalized healthcare solutions stimulates advancements in respiratory testing
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory and compliance challenges associated with respiratory disease testing solutions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Component: Rising prevalence of respiratory ailments accelerates the need for reagents & kits
  • 5.2.2. End Users: Growing importance of diagnostic laboratories as they facilitate high-throughput and detailed analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Respiratory Disease Testing Market, by Test Type

• 6.1. Introduction
• 6.2. Blood Tests
• 6.3. Imaging Tests
  • 6.3.1. Chest X-Ray
  • 6.3.2. Computed Tomography
• 6.4. Pulmonary Function Tests

7. Respiratory Disease Testing Market, by Component

• 7.1. Introduction
• 7.2. Instruments
• 7.3. Reagents & Kits
• 7.4. Software

8. Respiratory Disease Testing Market, by Age Group

• 8.1. Introduction
• 8.2. Adults
• 8.3. Geriatrics
• 8.4. Pediatrics

9. Respiratory Disease Testing Market, by Technology

• 9.1. Introduction
• 9.2. Imaging Technologies
• 9.3. Immunoassays
• 9.4. Microbiology
• 9.5. Molecular Diagnostics

10. Respiratory Disease Testing Market, by Test Purpose

• 10.1. Introduction
• 10.2. Diagnosis
• 10.3. Monitoring
• 10.4. Prognosis
• 10.5. Screening

11. Respiratory Disease Testing Market, by Diseases Type

• 11.1. Introduction
• 11.2. Asthma
• 11.3. Chronic Obstructive Pulmonary Disease (COPD)
  • 11.3.1. Chronic Bronchitis
  • 11.3.2. Emphysema
• 11.4. Infectious Respiratory Diseases
  • 11.4.1. Influenza
  • 11.4.2. Pneumonia
  • 11.4.3. Tuberculosis
• 11.5. Lung Cancer

12. Respiratory Disease Testing Market, by End Users

• 12.1. Introduction
• 12.2. Diagnostic Laboratories
• 12.3. Home Care Settings
• 12.4. Hospitals & Clinics
• 12.5. Research Laboratories

13. Americas Respiratory Disease Testing Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Respiratory Disease Testing Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Respiratory Disease Testing Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Scenario Analysis
  • 16.3.1. Roche enhances respiratory disease diagnostics with advanced multi-virus detection test technology
  • 16.3.2. NIH-backed study has developed an experimental blood test to predict severe respiratory diseases
  • 16.3.3. New national centre launched to improve tests and treatments for respiratory diseases
• 16.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. AstraZeneca PLC
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. Biomerieux PLC
• 6. Charles River Laboratories
• 7. COSMED srl
• 8. Eurofins Viracor, LLC
• 9. F. Hoffmann-La Roche Ltd.
• 10. Fujifilm Holdings
• 11. GE Healthcare
• 12. Koninklijke Philips N.V
• 13. Medtronic PLC
• 14. MGC Diagnostics Corporation by Caire Inc.
• 15. QIAGEN Group
• 16. ResMed
• 17. SDI Diagnostics, Inc.
• 18. Seegene Inc.
• 19. Seimens Healthineers AG
• 20. Thermo Fisher Scientific